t(12;13)(p13;q12) ETV6/FLT3

2014-03-01   Etienne De Braekeleer  , Etienne De Braekeleer  , Etienne De Braekeleer  

1.Cytogenetics Laboratory, Faculty of Medicine, University of Brest, France
2.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Clinics and Pathology

Disease

Acute lymphoblastic leukemia (ALL) and myeloid malignancies are described in cases of t(12;13)(p13;q12)

Note

The translocation t(12;13)(p13;q12) is molecularly heterogeneous:
The t(12;13)(p13;q12) with ETV6 and FLT3 involvement, herein described, was found in three cases of myeloproliferative neoplasm (MPN) with eosinophilia (Vu et al., 2006; Walz et al., 2011).
On the other hand, a t(12;13)(p13;q12) ETV6/CDX2 has been described in another case (Chase et al., 1999).
Finally, other cases of t(12;13)(p13;q12) without molecular ascertainment may or may not involve FLT3, CDX2, or even ETV6.

Epidemiology

All together, eleven cases of t(12;13)(p13;q12) were described.

Clinics

Three cases of t(12;13)(p13;q12) ETV6/FLT3 are reported:
A female patient aged 68 years, with a MPD with eosinophilia; she died 21 months after diagnosis.
A 60-year old man with a MPN with hypereosinophilia in accelerated phase; he died soon after diagnosis of infection and pancytopenia.
A 29-year old man who developed MPN with hypereosinophilia four weeks after autologous stem cell transplantation following a T-lymphoblastic lymphoma; he died 5 weeks after diagnosis of MPN.
Another case presents with a similar phenotype: a 49 year-old male patient, also with a MPN with eosinophilia; he died 11 months after diagnosis (and with a history of leukocytosis for last two years before diagnosis). No molecular analysis was performed (Chiyoda et al., 1994).
The case with ETV6/CDX2 involvement was a 66 year old male patient with M1 acute myeloid leukaemia (AML); he died 40 months after diagnosis.
The six other known patients with a t(12;13)(p13;q12) were two children and one 17 year-old female patient with acute lymphoblastic leukemia (ALL) (Keene et al., 1987; Wlodarska et al., 1998; Heerema et al., 2000) and three adult patients with myeloid diseases (one refractory anemia with excess of blasts (RAEB) and two AMLs; one of which was a treatment-related AML (t-AML)) (Knapp et al., 1985; Tosi et al., 1998; Clavio et al., 2001).

Cytology

All three patients with ETV6/FLT3 had myeloproliferative neoplasm with eosinophilia.

Genes Involved and Proteins

Note
In three patients, the ETV6/FLT3 implication was found (Vu et al., 2006; Walz et al., 2011). Following the first report, transgenic mice expressing ETV6-FLT3 were used (Baldwin et al., 2007). Expression of the fusion protein in the transgenic mice was found in spleen, bone marrow, thymus, and liver. A significant increase in the number of CFU-GM, BFU-E, CFU-S and CFU-GEMM was produced. Mice developed MPD with a high incidence but did not succumbed to leukemia (Baldwin et al., 2007).
Gene name
ETV6 (ets variant 6)
Location
12p13.2
Note
The ETV6 gene encodes a transcription factor frequently rearranged in myeloid and lymphoid leukemias.
Dna rna description
The ETV6 gene spans a region of less than 250 kb at band 12p13.1 and consists of 8 exons. There are two start codons, one (exon 1a starting at codon 1) located at the beginning of the gene and another alternative (exon 1b starting at codon 43) upstream of exon 3.
Protein description
The ETV6 protein (452 amino acids) contains two major domains, the HLH (helix-loop-helix) and ETS domains. The HLH domain, also referred to as the pointed or sterile alpha motif domain, is encoded by exons 3 and 4 and functions as a homo-oligodimerization domain. The ETS domain, encoded by exons 6 through 8, is responsible for sequence specific DNA-binding and protein-protein interaction. Transcriptional regulator; involved in bone marrow hematopoiesis.
Gene name
FLT3 (FMS-like tyrosine kinase 3)
Location
13q12.2
Note
FLT3 is one of the most frequently mutated genes in hematologic malignancies, being found in about 30% of AML patients and rarely in ALL patients (Gilliland and Griffin, 2002; Stirewalt and Radich, 2003).
Dna rna description
The FLT3 gene spans a region of 97 kb and consists of 24 exons.
Protein description
The FLT3 gene is a member of the receptor tyrosine kinase subclass III family of genes. It encodes a protein structurally related to the receptors for platelet derived growth factor. Contains five immunoglobulin-like domains in the extracellular domain involved in protein-ligand interaction, a transmembrane domain, and an intracellular tyrosine kinase domain. Dimerization induces kinase domain activation, leading to the activation of intracellular signalling pathways. Expressed on early hemopoietic progenitor cells.

Result of the Chromosomal Anomaly

Description

Both ETV6/FLT3 and FLT3/ETV6 transcripts were detected. However, FLT3/ETV6 transcripts were out of frame. Various in frame fusion products of ETV6/FLT3 were found. Fusion of exon 5 of ETV6 5 term to exon 14 of FLT3 3 term (and exon 4 and 16 in one transcript) (Vu et al., 2006).
In-frame fusion genes were observed between exon 4 or 5 of ETV6 and exon 14 of FLT3 (Walz et al., 2011).
Atlas Image
Schematic diagram of the ETV6, FLT3 and ETV6-FLT3 proteins.

Description

N-term Helix-loop-helix (HLH) oligodimerization domain of ETV6 fused to the transmembrane and tyrosine kinase domains of FLT3.

Oncogenesis

Constitutive tyrosine kinase activation of FLT3.

Highly cited references

Pubmed IDYearTitleCitations
217055012011Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.18
167610192006FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.12
248549882014ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.8
238732822014Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia.8
193456702009The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation.6
305593102018Two myeloid leukemia cases with rare FLT3 fusions.3
331669082020Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.2
294718952018ETV6/FLT3 Fusion Is a Novel Client Protein of Hsp90.2
231686132013Direct binding of Grb2 has an important role in the development of myeloproliferative disease induced by ETV6/FLT3.2
339907052021Myeloid/lymphoid neoplasms with FLT3 rearrangement.0
337926282021ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML.0
345954532020Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation.0

Article Bibliography

Pubmed IDLast YearTitleAuthors

Summary

Fusion gene

ETV6/FLT3 ETV6 (12p13.2) FLT3 (13q12.2) M t(12;13)(p13;q12)|ETV6/FLT3 ETV6 (12p13.2) FLT3 (13q12.2) TIC

Citation

Etienne De Braekeleer ; Etienne De Braekeleer ; Etienne De Braekeleer

t(12;13)(p13;q12) ETV6/FLT3

Atlas Genet Cytogenet Oncol Haematol. 2014-03-01

Online version: http://atlasgeneticsoncology.org/haematological/1495/deep-insight-explorer/js/teaching-explorer/

Historical Card

2007-12-01 t(12;13)(p13;q12) ETV6/FLT3 by  Jean-Loup Huret 

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France